• Verughese Jacob, Jeffrey A Reynolds, Sajal K Chattopadhyay, Keith Nowak, David P Hopkins, Erika Fulmer, Ami N Bhatt, Nicole L Therrien, Alison E Cuellar, Thomas E Kottke, John M Clymer, Kimberly J Rask, and Community Preventive Services Task Force.
• Community Guide Program, Office of Scientific Evidence and Recommendations, Office of Science, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: hir0@cdc.gov.
• Am J Prev Med. 2023 Oct 1; 65 (4): 735754735-754.

IntroductionThis paper examined the recent evidence from economic evaluations of team-based care for controlling high blood pressure.MethodsThe search covered studies published from January 2011 through January 2021 and was limited to those based in the U.S. and other high-income countries. This yielded 35 studies: 23 based in the U.S. and 12 based in other high-income countries. Analyses were conducted from May 2021 through February 2023. All monetary values reported are in 2020 U.S. dollars.ResultsThe median intervention cost per patient per year was $438 for U.S. studies and $299 for all studies. The median change in healthcare cost per patient per year after the intervention was -$140 for both U.S. studies and for all studies. The median net cost per patient per year was $439 for U.S. studies and $133 for all studies. The median cost per quality-adjusted life year gained was $12,897 for U.S. studies and $15,202 for all studies, which are below a conservative benchmark of $50,000 for cost-effectiveness.DiscussionIntervention cost and net cost were higher in the U.S. than in other high-income countries. Healthcare cost averted did not exceed intervention cost in most studies. The evidence shows that team-based care for blood pressure control is cost-effective, reaffirming the favorable cost-effectiveness conclusion reached in the 2015 systematic review.Published by Elsevier Inc.

19 keywords...

hide…